Stefan Pilz1, Ali Chakeri2, John Pa Loannidis3, Lukas Richter2, Verena Theiler-Schwetz1, Christian Trummer1, Robert Krause4, Franz Allerberger2. 1. Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. 2. Austrian Agency for Health and Food Safety (AGES), Vienna, Austria. 3. Departments of Medicine, Epidemiology and Population Health, Biomedical Data Science, and Statistics and Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, CA, USA. 4. Section of Infectious Diseases and Tropical Medicine, Medical University of Graz, Graz, Austria.
Abstract
BACKGROUND: A key question concerning coronavirus disease 2019 (COVID-19) is how effective and long lasting immunity against this disease is in individuals who were previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We aimed to evaluate the risk of SARS-CoV-2 re-infections in the general population in Austria. METHODS: This is a retrospective observational study using national SARS-CoV-2 infection data from the Austrian epidemiological reporting system. As the primary outcome, we aim to compare the odds of SARS-CoV-2 re-infections of COVID-19 survivors of the first wave (February to April 30, 2020) versus the odds of first infections in the remainder general population by tracking polymerase chain reaction (PCR)-confirmed infections of both groups during the second wave from September 1 to November 30, 2020. Re-infection counts are tentative, since it cannot be excluded that the positive PCR in the first and/or second wave might have been a false positive. RESULTS: We recorded 40 tentative re-infections in 14 840 COVID-19 survivors of the first wave (0.27%) and 253 581 infections in 8 885 640 individuals of the remaining general population (2.85%) translating into an odds ratio (95% confidence interval) of 0.09 (0.07 to 0.13). CONCLUSIONS: We observed a relatively low re-infection rate of SARS-CoV-2 in Austria. Protection against SARS-CoV-2 after natural infection is comparable with the highest available estimates on vaccine efficacies. Further well-designed research on this issue is urgently needed for improving evidence-based decisions on public health measures and vaccination strategies.
BACKGROUND: A key question concerning coronavirus disease 2019 (COVID-19) is how effective and long lasting immunity against this disease is in individuals who were previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We aimed to evaluate the risk of SARS-CoV-2 re-infections in the general population in Austria. METHODS: This is a retrospective observational study using national SARS-CoV-2 infection data from the Austrian epidemiological reporting system. As the primary outcome, we aim to compare the odds of SARS-CoV-2 re-infections of COVID-19 survivors of the first wave (February to April 30, 2020) versus the odds of first infections in the remainder general population by tracking polymerase chain reaction (PCR)-confirmed infections of both groups during the second wave from September 1 to November 30, 2020. Re-infection counts are tentative, since it cannot be excluded that the positive PCR in the first and/or second wave might have been a false positive. RESULTS: We recorded 40 tentative re-infections in 14 840 COVID-19 survivors of the first wave (0.27%) and 253 581 infections in 8 885 640 individuals of the remaining general population (2.85%) translating into an odds ratio (95% confidence interval) of 0.09 (0.07 to 0.13). CONCLUSIONS: We observed a relatively low re-infection rate of SARS-CoV-2 in Austria. Protection against SARS-CoV-2 after natural infection is comparable with the highest available estimates on vaccine efficacies. Further well-designed research on this issue is urgently needed for improving evidence-based decisions on public health measures and vaccination strategies.
Authors: Stijn P Andeweg; Harry Vennema; Mirjam J Knol; Dirk Eggink; Irene Veldhuijzen; Naomi Smorenburg; Dennis Schmitz; Florian Zwagemaker; Arianne B van Gageldonk-Lafeber; Susan J M Hahné; Chantal Reusken Journal: Sci Transl Med Date: 2022-07-21 Impact factor: 19.319
Authors: Viviana Simon; Vamsi Kota; Ryan F Bloomquist; Hannah B Hanley; David Forgacs; Savita Pahwa; Suresh Pallikkuth; Loren G Miller; Joanna Schaenman; Michael R Yeaman; David Manthei; Joshua Wolf; Aditya H Gaur; Jeremie H Estepp; Komal Srivastava; Juan Manuel Carreño; Frans Cuevas; Ali H Ellebedy; Aubree Gordon; Riccardo Valdez; Sarah Cobey; Elaine F Reed; Ravindra Kolhe; Paul G Thomas; Stacey Schultz-Cherry; Ted M Ross; Florian Krammer Journal: mSphere Date: 2022-05-19 Impact factor: 5.029
Authors: Snežana Medić; Cleo Anastassopoulou; Zagorka Lozanov-Crvenković; Vladimir Vuković; Nataša Dragnić; Vladimir Petrović; Mioljub Ristić; Tatjana Pustahija; Zoran Gojković; Athanasios Tsakris; John P A Ioannidis Journal: Lancet Reg Health Eur Date: 2022-07-01
Authors: Sissy Therese Sonnleitner; Martina Prelog; Bianca Jansen; Chantal Rodgarkia-Dara; Sarah Gietl; Carmen Maria Schönegger; Stephan Koblmüller; Christian Sturmbauer; Wilfried Posch; Giovanni Almanzar; Hanna Jury; Tom Loney; Alexander Tichy; Norbert Nowotny; Gernot Walder Journal: Transbound Emerg Dis Date: 2021-05-27 Impact factor: 4.521
Authors: Eamon O Murchu; Paula Byrne; Paul G Carty; Cillian De Gascun; Mary Keogan; Michelle O'Neill; Patricia Harrington; Máirín Ryan Journal: Rev Med Virol Date: 2021-05-27 Impact factor: 11.043